As of September 2014, 90 patients were disease - free, including 7 patients who had been treated for
recurrent esophageal cancer during the first 5 years.
Currently, the CDK9 inhibitor flavopiridol is being evaluated in several phase I and II clinical trials for its anti-
cancer effects either as a single agent or in combination with other drugs in treatment of
esophageal cancer, B - cell chronic lymphocytic leukemia, endometrial carcinoma,
recurrent / metastatic squamous cell carcinoma and most relevantly, previously treated locally advanced or metastatic breast
cancer (http://www.cancernetwork.com/review-article/current-clinical-trials-flavopiridol/page/0/2).